Edition:
India

Crinetics Pharmaceuticals Inc (CRNX.OQ)

CRNX.OQ on NASDAQ Stock Exchange Global Select Market

32.82USD
11:38pm IST
Change (% chg)

$-0.76 (-2.26%)
Prev Close
$33.58
Open
$33.31
Day's High
$34.50
Day's Low
$32.75
Volume
12,907
Avg. Vol
23,417
52-wk High
$40.78
52-wk Low
$19.25

Summary

Name Age Since Current Position

Wendall Wierenga

70 Chairman of the Board

R. Scott Struthers

Chief Executive Officer, Co-Founder, Director

Stephen Betz

Co-Founder, Vice President - Biology

Yun-Fei Zhu

Co-Founder, Vice President - Chemistry

Marc Wilson

Chief Financial Officer

Ajay Madan

Vice President - Development

Biographies

Name Description

Wendall Wierenga

Dr. Wendall Wierenga, Ph.D., is Chairman of the Board of the Company. Dr. Wierenga brings more than 40 years of biotechnology and pharmaceutical experience in small, medium and large companies. He has been an advisor to Crinetics since its inception and recently retired as executive vice president, research and development at Santarus. Dr. Wierenga is on the board of director’s at XenoPort, Cytokinetics, Ocera Therapeutics, Apricus Biosciences, and SRI International, as well as on the scientific advisory boards at Concert Pharmaceuticals, aTyr Pharmaceuticals, and the Ferring Research Institute. He previously served as executive vice president of R&D at Neurocrine Biosciences and Ambit Biosciences. Prior to Neurocrine, he served as chief executive officer of Syrrx, Inc. (now Takeda San Diego) and as senior vice president of worldwide pharmaceutical sciences, technologies and development at Parke-Davis/Warner Lambert (now Pfizer), where he was responsible for worldwide drug development. Prior to joining Parke-Davis, Wierenga spent 16 years at Upjohn Pharmaceuticals, where he led cancer and infectious diseases research and later drug discovery research. He led/participated in the research and development of more than 16 NDAs and 16 marketed products, including Lipitor®, Neurontin®, and Uceris®. He is an author of more than 60 scientific papers and inventor on 30 patents. Dr. Wierenga holds a B.A. from Hope College and Ph.D. in chemistry from Stanford University.

R. Scott Struthers

Dr. R. Scott Struthers, Ph.D., is Chief Executive Officer, Co-Founder and Director of the Company. Dr. Struthers is a founder of Crinetics. Prior to Crinetics, he was senior director and head, endocrinology and metabolism at Neurocrine Biosciences. At Neurocrine, he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists. This resulted in a first-in-class compound, elagolix, which has demonstrated safety and efficacy in over 40 clinical trials totaling more than 3,000 patients. Prior to Neurocrine, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. Dr. Struthers is an author of more than 75 scientific publications. He holds Ph.D. in physiology and pharmacology from the University of California, San Diego.

Stephen Betz

Dr. Stephen F. Betz, Ph.D., is Co-Founder and Vice President - Biology of the Company. Dr. Betz is a founder of Crinetics. Prior to Crinetics, he was director of endocrinology and metabolism at Neurocrine Biosciences and worked on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets. Prior to Neurocrine, he led laboratory efforts at GeneFormatics, and at Abbott Laboratories worked in pharmaceutical discovery, including structure-guided drug design, assay development, and compound screening in the Research NMR Group. He holds a B.S. in chemistry from the University of Delaware and Ph.D. in chemistry from the University of North Carolina at Chapel Hill.

Yun-Fei Zhu

Dr. Yun-Fei (Frank) Zhu, Ph.D., is Co-Founder and Vice President - Chemistry of the Company. Dr. Zhu is a founder of Crinetics. Prior to Crinetics, he was director of chemistry in the endocrinology and metabolism group at Neurocrine Biosciences. At Neurocrine, he led chemistry discovery of nonpeptide GnRH antagonists. His research involved discovery of small molecule inhibitors of several neuropeptide receptors including CRFR2, MCH receptor, and GnRH for the treatment of a range of endocrine diseases. Prior to Neurocrine, he worked at CombiChem and BioResearch. He holds a B.S. in chemistry from Hangzhou University and Ph.D. in organic chemistry from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.

Marc Wilson

Mr. Marc Wilson is Chief Financial Officer of the Company. Prior to Crinetics, Marc was Vice President of Finance and Accounting and Chief Accounting Officer at Cidara Therapeutics. There, he led the accounting and finance functions following its Series A financing and through its initial public offering. Prior to Cidara, Mr. Wilson was Director of Accounting and Controller at Trius Therapeutics until its acquisition by Cubist Pharmaceuticals. Prior to Trius, Mr. Wilson was an Accounting Manager at Neurocrine Biosciences. He began his career with PricewaterhouseCoopers LLP and is a certified public accountant. Mr. Wilson earned a bachelor’s degree in Economics and Accounting from the College of the Holy Cross.

Ajay Madan

Dr. Ajay Madan is Vice President - Development of the Company. Prior to Crinetics, he was vice president of preclinical development at Neurocrine Biosciences. At Neurocrine, he was responsible for bioanalytical analysis, drug metabolism, pharmacokinetics, toxicology, and clinical pharmacology in support of a number of drug discovery and development programs. He also initiated and led the vesicular monoamine transporter 2 (VMAT2) inhibitor program for the treatment of tardive dyskinesia, resulting in the discovery of a best-in-class compound, valbenazine. Valbenazine has demonstrated efficacy and safety in Phase 2 and 3 clinical trials and was awarded fast-track status and breakthrough therapy designation by the FDA. Prior to Neurocrine, he was the chief scientific officer at XenoTech L.L.C., a research company that led the innovation of the current in vitro drug interaction platforms routinely used by all drug discovery and development companies. Dr. Madan is an author of more than 50 scientific publications, and he has been a diplomate of the American Board of Toxicology since 2005. He holds a B.Pharm. degree from Birla Institute of Technology and a Ph.D. in pharmacology and toxicology from the University of Kansas.

Basic Compensation

Options Compensation